English (United Kingdom)

https://curated-unify.zendy.io/wp-json/zendy-region/v1/featured_content/oa?rat=en

https://curated-unify.zendy.io/wp-json/zendy-region/v1/highlighted_journal/

Global: Zendy Plus annual

Presents the access of premium content as premium feature

Premium Content

Presents the keyphrase highlighting as premium feature

Keyphrase Highlighting

Presents the summarisation as premium feature

Summarisation

Insights

Presents the pdf analysis as premium feature

PDF Analysis

Presents the zaia usage as premium feature

ZAIA

Global: Zendy Tools annual

Global: Zendy Free Plan

Global: Zendy Tools monthly

Global: Zendy Plus monthly

Sickle Cell Anemia (SCA) is a globally prevalent, monogenic, life-threatening blood disorder with a complex pathology that remains obscure. A deepened understanding of the malady in the recent years has led to pharmaceutical advancements that target pathophysiology and ultimately ameliorate associated multivariate clinical manifestations. Abnormal cell to cell interactions, endothelial adhesion, induced oxidative stress, intracellular erythrocyte dehydration and concentration levels of fetal hemoglobin are a few factors know to play a key role in microvascular obstruction in individuals with hemoglobin S. All of which have recently been manipulated in-vitro to pharmaceutically alter clinical complications, disease progression and mortality patterns. The purpose of this paper is to provide a condensed overview of recent discoveries made within SCA pathology and subsequent pathologic based therapeutic agents. A general overview of the molecular basis of the malady, global prevalence and the efforts toward advancing stem cell transplantation technology will also be discussed.

Sickle Cell Anemia: A Succinct Look into Recently Tested Disease Modifying Interventions